| Symbol | INTS |
|---|---|
| Name | INTENSITY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1 ENTERPRISE DRIVE,SUITE 430, SHELTON, Connecticut, 06484, United States |
| Telephone | 203-221-7381 |
| Fax | — |
| — | |
| Website | https://www.intensitytherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001567264 |
| Description | Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Companys lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibbs anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Additional info from NASDAQ: |
(30% Negative) INTENSITY THERAPEUTICS, INC. (INTS) Reports Q3 2026 Financial Results
Read moreIntensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreIntensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreIntensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Read moreDirector DUBIN THOMAS I H 🟢 acquired 5.5K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000002
Read moreDirector Donovan Daniel 🟢 acquired 5.5K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000002
Read moreDirector GOLDBERG MARK A 🟢 acquired 5.5K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000002
Read moreDirector Leahy Emer 🟢 acquired 5.5K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000002
Read moreWesolowski John M 🟢 acquired 11.0K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000008
Read moreTalamo Joseph 🟢 acquired 34.0K shares (1 derivative) of INTENSITY THERAPEUTICS, INC. (INTS) at $4.90 Transaction Date: Jul 16, 2026 | Filing ID: 000009
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06263231 | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to U… | Phase3 | Sarcoma,Soft Tissue | Recruiting | 2024-06-28 | 2028-12-01 | ClinicalTrials.gov |
| NCT04781725 | INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer | Phase2 | Breast Cancer | Unknown | 2021-03-25 | 2023-03-01 | ClinicalTrials.gov |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | Phase1 | Breast Cancer | Completed | 2017-02-09 | 2023-02-22 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pazopanib | Other | Phase PHASE3 | Sarcoma,Soft Tissue | RECRUITING | NCT06263231 |
| Trabectedin | Other | Phase PHASE3 | Sarcoma,Soft Tissue | RECRUITING | NCT06263231 |
| Eribulin | Other | Phase PHASE3 | Sarcoma,Soft Tissue | RECRUITING | NCT06263231 |
| INT230-6 | Other | Phase PHASE3 | Sarcoma,Soft Tissue | RECRUITING | NCT06263231 |
| Saline injection | Other | Phase PHASE2 | Breast Cancer | UNKNOWN | NCT04781725 |
| INT230-6 | Other | Phase PHASE2 | Breast Cancer | UNKNOWN | NCT04781725 |
| anti-CTLA-4 antibody | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03058289 |
| anti-PD-1 antibody | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03058289 |
| INT230-6 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03058289 |
| Pazopanib | Other | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Trabectedin | Other | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Eribulin | Other | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| INT230-6 | Other | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Pazopanib | DRUG | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Trabectedin | DRUG | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Eribulin | DRUG | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |
| Saline injection | OTHER | Phase PHASE2 | Breast Cancer | UNKNOWN | NCT04781725 |
| anti-CTLA-4 antibody | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03058289 |
| anti-PD-1 antibody | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT03058289 |
| INT230-6 | DRUG | Phase PHASE3 | Sarcoma,Soft Tissue | ACTIVE_NOT_RECRUITING | NCT06263231 |